Middle East and Africa Monoclonal Antibodies Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)


No. of Pages: 152    |    Report Code: TIPRE00028620    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
Middle East and Africa Monoclonal Antibodies Market

The Middle East & Africa monoclonal antibodies market is expected to reach US$ 5,741.1 million by 2028 from US$ 3,198.9 million in 2021. The market is estimated to grow at a CAGR of 8.7% from 2021–2028.

The high focus of pharmaceutical giants on developing novel monoclonal antibodies resulted in significant research collaborations that can pave the way to key market share in the coming years. New manufacturers seek strategic collaborations to increase uptake of such novel techniques, as they intend to enter a highly competitive market to sustain their position. For records, in October 2017, Incyte and MacroGenics, Inc. announced a partnership and license agreement for "MGA012", an investigational monoclonal antibody of MacroGenics, Inc. Such factors are projected to support the Middle East & Africa market growth in the coming years. Furthermore, strategic research collaborations also play a vital role in detecting pharmacological actions of mABs soon after the diagnosis.

 

The demand for monoclonal antibody-based products in Saudi Arabia have a high success rate in clinical development and is reported that the probability of FDA approvals for mABs in Phase 1 of development in ~14.1% that is almost twice the approval rate of small molecule drugs (~7.6%). On the other hand, the IAVI report states that with the onset of pandemic worldwide many biopharmaceutical companies sell mABs based products at affordable prices. For example, in South Africa, Roche sells its breast cancer mAB "trastuzumab" as both Herceptin the original brand as a second brand called "Hercelon". Apart from that, as availability of these mABs is limited, various pharmaceutical companies are conducting clinical trials in middle-income counties. For example, Merck is conducting clinical trials in several middle-income countries such as South Africa, Colombia, and Malaysia. Such aforementioned factors have positive influence in the regional market thereby witnessing high adoption of monoclonal antibody in Middle East and Africa region amid COVID-19 pandemic.

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The Middle East & Africa monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.

 

Middle East & Africa Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report

Middle East and Africa Monoclonal Antibodies Strategic Insights

Strategic insights for the Middle East and Africa Monoclonal Antibodies provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/middle-east-and-africa-monoclonal-antibodies-market-strategic-framework.webp
Get more information on this report

Middle East and Africa Monoclonal Antibodies Report Scope

Report Attribute Details
Market size in 2021 US$ 3,198.9 Million
Market Size by 2028 US$ 5,741.1 Million
Global CAGR (2021 - 2028) 8.7%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Source
  • Human
  • Humanized
  • Chimeric
  • Murine
By Production Method
  • In-Vitro
  • In-Vivo
By Indication
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Inflammatory Diseases
  • Microbial Diseases
By Application
  • Therapeutic Applications
  • Diagnostic Applications
  • Research Applications
By End-User
  • Hospitals
  • Research Institutes
Regions and Countries Covered Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Amgen Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Get more information on this report

    Middle East and Africa Monoclonal Antibodies Regional Insights

    The geographic scope of the Middle East and Africa Monoclonal Antibodies refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/middle-east-and-africa-monoclonal-antibodies-market-geography.webp
    Get more information on this report

    Middle East & Africa Monoclonal Antibodies Market Segmentation      

     

    By Source

    • Human
    • Humanized
    • Chimeric
    • Murine 

    By Production Method

    • In-Vitro
    • In-Vivo

    By Indication

    • Cancer
    • Autoimmune Diseases
    • Infectious Diseases
    • Inflammatory Diseases
    • Microbial Diseases
    • Others

    By Application

    • Therapeutic Applications
    • Diagnostic Applications
    • Research Applications

    By End-User

    • Hospitals
    • Research Institutes
    • Others

    By Country

    • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

    Companies Mentioned

    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc.
    • Amgen Inc
    • DAIICHI SANKYO COMPANY, LIMITED
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca
    • Bayer AG
    • Bristol-Myers Squibb Company

    The List of Companies - Middle East and Africa Monoclonal Antibodies Market

    1. Novartis AG
    2. Pfizer Inc.
    3. GlaxoSmithKline plc.
    4. Amgen Inc
    5. DAIICHI SANKYO COMPANY, LIMITED
    6. F. Hoffmann-La Roche Ltd.
    7. AstraZeneca
    8. Bayer AG
    9. Bristol-Myers Squibb Company
    Frequently Asked Questions
    How big is the Middle East and Africa Monoclonal Antibodies Market?

    The Middle East and Africa Monoclonal Antibodies Market is valued at US$ 3,198.9 Million in 2021, it is projected to reach US$ 5,741.1 Million by 2028.

    What is the CAGR for Middle East and Africa Monoclonal Antibodies Market by (2021 - 2028)?

    As per our report Middle East and Africa Monoclonal Antibodies Market, the market size is valued at US$ 3,198.9 Million in 2021, projecting it to reach US$ 5,741.1 Million by 2028. This translates to a CAGR of approximately 8.7% during the forecast period.

    What segments are covered in this report?

    The Middle East and Africa Monoclonal Antibodies Market report typically cover these key segments-

    • Source (Human, Humanized, Chimeric, Murine)
    • Production Method (In-Vitro, In-Vivo)
    • Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases)
    • Application (Therapeutic Applications, Diagnostic Applications, Research Applications)
    • End-User (Hospitals, Research Institutes)

    What is the historic period, base year, and forecast period taken for Middle East and Africa Monoclonal Antibodies Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Monoclonal Antibodies Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Middle East and Africa Monoclonal Antibodies Market?

    The Middle East and Africa Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Amgen Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Who should buy this report?

    The Middle East and Africa Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East and Africa Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.